Trk inhibitor

DRUG CLASS:

Trk inhibitor

News alerts, weekly reports and conference planners

Related drugs:

NTRK1 fusion	Solid Tumor	NTRK1 fusion	Solid Tumor	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1
NTRK3 fusion	Solid Tumor	NTRK3 fusion	Solid Tumor	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1
NTRK2 fusion	Solid Tumor	NTRK2 fusion	Solid Tumor	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1
NTRK3 fusion	Biliary Tract Cancer	NTRK3 fusion	Biliary Tract Cancer	Trk inhibitor Sensitive: A2 - Guideline Trk inhibitor Sensitive : A2	Trk inhibitor Sensitive: A2 - Guideline Trk inhibitor Sensitive : A2
NTRK2 fusion	Biliary Tract Cancer	NTRK2 fusion	Biliary Tract Cancer	Trk inhibitor Sensitive: A2 - Guideline Trk inhibitor Sensitive : A2	Trk inhibitor Sensitive: A2 - Guideline Trk inhibitor Sensitive : A2
NTRK1 fusion	Biliary Tract Cancer	NTRK1 fusion	Biliary Tract Cancer	Trk inhibitor Sensitive: A2 - Guideline Trk inhibitor Sensitive : A2	Trk inhibitor Sensitive: A2 - Guideline Trk inhibitor Sensitive : A2
ROS1 rearrangement	Non Small Cell Lung Cancer	ROS1 rearrangement	Non Small Cell Lung Cancer	repotrectinib Sensitive: A2 - Guideline repotrectinib Sensitive : A2	repotrectinib Sensitive: A2 - Guideline repotrectinib Sensitive : A2
NTRK3 fusion	Solid Tumor	NTRK3 fusion	Solid Tumor	Trk inhibitor Sensitive: B - Late Trials Trk inhibitor Sensitive : B	Trk inhibitor Sensitive: B - Late Trials Trk inhibitor Sensitive : B
NTRK2 fusion	Solid Tumor	NTRK2 fusion	Solid Tumor	Trk inhibitor Sensitive: B - Late Trials Trk inhibitor Sensitive : B	Trk inhibitor Sensitive: B - Late Trials Trk inhibitor Sensitive : B
NTRK1 fusion	Solid Tumor	NTRK1 fusion	Solid Tumor	Trk inhibitor Sensitive: B - Late Trials Trk inhibitor Sensitive : B	Trk inhibitor Sensitive: B - Late Trials Trk inhibitor Sensitive : B
ROS1 positive	Solid Tumor	ROS1 positive	Solid Tumor	repotrectinib Sensitive: C1 - Off-label repotrectinib Sensitive : C1	repotrectinib Sensitive: C1 - Off-label repotrectinib Sensitive : C1
NTRK1 fusion	Non Small Cell Lung Cancer	NTRK1 fusion	Non Small Cell Lung Cancer	repotrectinib Sensitive: C1 - Off-label repotrectinib Sensitive : C1	repotrectinib Sensitive: C1 - Off-label repotrectinib Sensitive : C1
NTRK3 fusion	Non Small Cell Lung Cancer	NTRK3 fusion	Non Small Cell Lung Cancer	repotrectinib Sensitive: C1 - Off-label repotrectinib Sensitive : C1	repotrectinib Sensitive: C1 - Off-label repotrectinib Sensitive : C1
NTRK2 fusion	Non Small Cell Lung Cancer	NTRK2 fusion	Non Small Cell Lung Cancer	repotrectinib Sensitive: C1 - Off-label repotrectinib Sensitive : C1	repotrectinib Sensitive: C1 - Off-label repotrectinib Sensitive : C1
ROS1 fusion	Non Small Cell Lung Cancer	ROS1 fusion	Non Small Cell Lung Cancer	repotrectinib Sensitive: C2 – Inclusion Criteria repotrectinib Sensitive : C2	repotrectinib Sensitive: C2 – Inclusion Criteria repotrectinib Sensitive : C2
ROS1 G2032R	Non Small Cell Lung Cancer	ROS1 G2032R	Non Small Cell Lung Cancer	repotrectinib Sensitive: C3 – Early Trials repotrectinib Sensitive : C3	repotrectinib Sensitive: C3 – Early Trials repotrectinib Sensitive : C3
ALK positive	Solid Tumor	ALK positive	Solid Tumor	repotrectinib Sensitive: C3 – Early Trials repotrectinib Sensitive : C3	repotrectinib Sensitive: C3 – Early Trials repotrectinib Sensitive : C3
LMNA-NTRK1 fusion + NTRK1 G595R	Cholangiocarcinoma	LMNA-NTRK1 fusion + NTRK1 G595R	Cholangiocarcinoma	repotrectinib Sensitive: C3 – Early Trials repotrectinib Sensitive : C3	repotrectinib Sensitive: C3 – Early Trials repotrectinib Sensitive : C3
ROS1 fusion + ROS1 G2032R	Non Small Cell Lung Cancer	ROS1 fusion + ROS1 G2032R	Non Small Cell Lung Cancer	repotrectinib Sensitive: C3 – Early Trials repotrectinib Sensitive : C3	repotrectinib Sensitive: C3 – Early Trials repotrectinib Sensitive : C3
PRDX1 exon 5-NTRK1 exon 12 fusion	Lung Adenocarcinoma	PRDX1 exon 5-NTRK1 exon 12 fusion	Lung Adenocarcinoma	Trk inhibitor Sensitive: C4 – Case Studies Trk inhibitor Sensitive : C4	Trk inhibitor Sensitive: C4 – Case Studies Trk inhibitor Sensitive : C4
DCTN1-NTRK1 fusion	Soft Tissue Sarcoma	DCTN1-NTRK1 fusion	Soft Tissue Sarcoma	BAY 2731954 Resistant: C4 – Case Studies BAY 2731954 Resistant : C4	BAY 2731954 Resistant: C4 – Case Studies BAY 2731954 Resistant : C4
CD74-ROS1 fusion	Non Small Cell Lung Cancer	CD74-ROS1 fusion	Non Small Cell Lung Cancer	repotrectinib Resistant: C4 – Case Studies repotrectinib Resistant : C4	repotrectinib Resistant: C4 – Case Studies repotrectinib Resistant : C4
TPM3-NTRK1 G595R	Colon Cancer	TPM3-NTRK1 G595R	Colon Cancer	FCN-098 Sensitive: D – Preclinical FCN-098 Sensitive : D	FCN-098 Sensitive: D – Preclinical FCN-098 Sensitive : D
ETV6-NTRK3 G623R	Colon Cancer	ETV6-NTRK3 G623R	Colon Cancer	FCN-098 Sensitive: D – Preclinical FCN-098 Sensitive : D	FCN-098 Sensitive: D – Preclinical FCN-098 Sensitive : D
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib + repotrectinib Sensitive: D – Preclinical sotorasib + repotrectinib Sensitive : D	sotorasib + repotrectinib Sensitive: D – Preclinical sotorasib + repotrectinib Sensitive : D
ETV6-NTRK3 fusion	Neuroblastoma	ETV6-NTRK3 fusion	Neuroblastoma	repotrectinib Sensitive: D – Preclinical repotrectinib Sensitive : D	repotrectinib Sensitive: D – Preclinical repotrectinib Sensitive : D
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	trametinib + repotrectinib Sensitive: D – Preclinical trametinib + repotrectinib Sensitive : D	trametinib + repotrectinib Sensitive: D – Preclinical trametinib + repotrectinib Sensitive : D
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	trametinib + repotrectinib Sensitive: D – Preclinical trametinib + repotrectinib Sensitive : D	trametinib + repotrectinib Sensitive: D – Preclinical trametinib + repotrectinib Sensitive : D
NTRK3 fusion	Solid Tumor	NTRK3 fusion	Solid Tumor	SIM1803-1A Sensitive: D – Preclinical SIM1803-1A Sensitive : D	SIM1803-1A Sensitive: D – Preclinical SIM1803-1A Sensitive : D
NTRK2 fusion	Solid Tumor	NTRK2 fusion	Solid Tumor	SIM1803-1A Sensitive: D – Preclinical SIM1803-1A Sensitive : D	SIM1803-1A Sensitive: D – Preclinical SIM1803-1A Sensitive : D
NTRK1 fusion	Solid Tumor	NTRK1 fusion	Solid Tumor	SIM1803-1A Sensitive: D – Preclinical SIM1803-1A Sensitive : D	SIM1803-1A Sensitive: D – Preclinical SIM1803-1A Sensitive : D

Trk inhibitor

Trk inhibitor

Associations(45)

Associations
(45)